Latest News

Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics

The deal includes a $310 million upfront payment plus milestones for three IFM Tre assets – one clinical drug for NASH and atherosclerosis and two preclinical molecules.

Source link

Related posts

Pear-shaped body is healthier than apple shape


Banning tobacco sales to under 21s could have significant impacts on population health


FDA approves esketamine, the first major depression treatment to reach U.S. market in decades


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy